Rohit Gosain, MD

COLLISION: Surgery vs Thermal Ablation for Small-Size Colorectal Liver Mets

Mark A. Lewis, MD, discusses recent data from the COMMIT trial investing first-line treatment of patients with deficient DNA mismatch repair or microsatellite instability–high metastatic colorectal cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

TRANSMET: Chemotherapy Plus Liver Transplant in Unresectable Colorectal Liver Metastases

The Oncology Brothers and Mark A. Lewis, MD, review recent updates from the COLLISION study that were presented at the 2024 ASCO Annual Meeting.

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

Key Updates from ARMANI in Advanced HER2- Gastric/GEJ Cancer

Medical oncologists review recent data from the TRANSMET study evaluating chemotherapy plus liver transplantation in patients with unresectable colorectal liver metastases.

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

Recent Updates from the ESOPEC Trial in Esophageal Adenocarcinoma

Mark A. Lewis, MD, and the Oncology Brothers discuss recent updates from the ARMANI trial in HER2- gastric/ gastroesophageal junction cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD

PSMAfore: Health-Related QoL and Pain in Taxane-Naïve Patients with mCRPC

Following ASCO 2024, Mark A. Lewis, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide comprehensive insights on recent updates from the ESOPEC trial in esophageal adenocarcinoma.

Toni K. Choueiri, MD, with the Oncology Brothers presenting slides

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD

Real-World Evidence from the IMDC

Toni Choueiri, MD, and the Oncology Brothers discuss the PSMAfore study evaluating health-related quality of life and pain in taxane-naïve patients with metastatic castration-resistant prostate cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD

KIM-1: Biomarker Analysis in IMmotion010 in RCC

Medical oncologists discuss how real-world evidence from the IMDC is informing treatment decisions in GU cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD

The Role of ctDNA in Genitourinary Cancer

Focusing on renal cell carcinoma, the Oncology Brothers and Toni Choueiri, MD, discuss KIM-1, a biomarker analysis in IMmotion010.

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD

EV-302: Patient-Reported Outcomes from EV+Pembro in mUC

Toni Choueiri, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in treatment paradigms for patients with genitourinary cancers.

Rahul Gosain, MD;Rohit Gosain, MD;Toni K. Choueiri, MD

Recent Data from JBCRG-M06/EMERALD in HER2+ Breast Cancer

Following ASCO 2024, Toni Choueiri, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent updates from the EV-302 study investigating enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

Erika P. Hamilton, MD, and the Oncology Brothers presenting slides

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD

Key Updates from DESTINY-Breast06

Focusing on HER2+ breast cancer, Erika P. Hamilton, MD, and the Oncology Brothers review data from JBCRG-M06/EMERALD looking at trastuzumab and pertuzumab in combination with eribulin or a taxane in locally advanced or metastatic disease.

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD

INAVO120: Inavolisib Combination Therapy in PIK3CA-Mutated Breast Cancer

Erika P. Hamilton, MD, and the Oncology Brothers review exciting data from DESTINY-Breast06 and discuss its impact on the evolving treatment landscape.

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD

Recent Updates from the postMONARCH Study

Medical oncologists discuss the INAVO120 study, which is evaluating inavolisib combination therapy in patients with PIK3CA-mutated breast cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD

RxPONDER: Use of AMH Levels in Premenopausal Women

The Oncology Brothers and Erika P. Hamilton, MD, discuss the postMONARCH study investigating fulvestrant alone vs fulvestrant plus abemaciclib.

Rahul Gosain, MD;Rohit Gosain, MD;Erika P. Hamilton, MD

ADRIATIC: Durvalumab as Consolidation Treatment for Limited-Stage SCLC

Following ASCO 2024, Erika P. Hamilton, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to review recent updates from the RxPONDER trial investigating the use of AMH levels in premenopausal women.

The Oncology Brothers with Joshua K. Sabari, MD, presenting slides

Rahul Gosain, MD;Rohit Gosain, MD;Joshua K. Sabari, MD

Results from CROWN: Lorlatinib in Treatment-Naïve Patients with Advanced ALK+ NSCLC

Joshua K. Sabari, MD, and the Oncology Brothers discuss recent findings from the ADRIATIC study focused on durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Joshua K. Sabari, MD

PALOMA-3: Subcutaneous Amivantamab in Refractory EGFR-Mutated Advanced NSCLC

The Oncology Brothers and Joshua K. Sabari, MD, provide expert perspectives on recent updates from the CROWN trial investigating lorlatinib in treatment-naïve advanced ALK+ non–small cell lung cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Joshua K. Sabari, MD

Recent Updates from MARIPOSA on Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC

Expert perspectives on recent data from the PALOMA-3 study investigating subcutaneous amivantamab in patients with refractory EGFR-mutated advanced non–small cell lung cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Joshua K. Sabari, MD

LAURA: Osimertinib after Definitive CRT in Unresectable Stage III NSCLC with EGFR Mutations

Joshua K. Sabari, MD, discusses recent updates from the MARIPOSA study, which is investigating amivantamab plus lazertinib in the first line in patients with EGFR-mutated advanced non–small cell lung cancer.

Rahul Gosain, MD;Rohit Gosain, MD;Joshua K. Sabari, MD

Understanding the Role of Zanubrutinib for the Treatment of CLL

Following ASCO 2024, Joshua K. Sabari, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the LAURA trial investigating osimertinib following definitive chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer with EGFR mutations.

Rohit Gosain, MD;Rahul Gosain, MD

April 23rd 2024

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Thomas Powles, MBBS, MRCP, MD, with Rohit Gosain, MD, and Rahul Gosain, MD, presenting slides

The Role of Circulating Tumor DNA in Bladder Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Thomas Powles, MD, MBBS, MRCP

Safety Profile Considerations for Enfortumab Vedotin Plus Pembrolizumab

Following a discussion centered on the EV-302 study, Thomas Powles, MBBS, MRCP, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in urothelial cancer.

Rohit Gosain, MD;Rahul Gosain, MD;Thomas Powles, MD, MBBS, MRCP

The Role of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

A comprehensive discussion on treatment-related adverse events seen in patients receiving enfortumab vedotin and pembrolizumab.

Rohit Gosain, MD;Rahul Gosain, MD;Thomas Powles, MD, MBBS, MRCP

EV-302 Study Design and Results

The Oncology Brothers are joined by Thomas Powles, MBBS, MRCP, MD, to discuss the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.

Rohit Gosain, MD;Rahul Gosain, MD;Thomas Powles, MD, MBBS, MRCP

Key Takeaways on Zanubrutinib Data

Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers to discuss the study design and results of the EV-302 trial investigating enfortumab vedotin plus pembrolizumab in untreated advanced urothelial carcinoma.

Rahul Gosain, MD; Rohit Gosain, MD; and Mazyar Shadman, MD, MPH, presenting slides

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

Zanubrutinib Safety Profile in CLL

Following a discussion on zanubrutinib that highlighted clinical trial data, treatment practices, and adverse event considerations, the Oncology Brothers offer concluding thoughts.

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

Efficacy of Zanubrutinib vs Acalabrutinib in R/R CLL: A Matching-Adjusted Indirect Comparison

Mazyar Shadman, MD, MPH, provides clinical insights on adverse events seen with zanubrutinib in patients with chronic lymphocytic leukemia.

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH

ALPINE: Zanubrutinib or Ibrutinib in Relapsed/Refractory CLL

A comprehensive discussion on a matching-adjusted indirect comparison study investigating the efficacy of zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Rahul Gosain, MD;Rohit Gosain, MD;Mazyar Shadman, MD, MPH